Compare ENR & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | MLTX |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2015 | 2020 |
| Metric | ENR | MLTX |
|---|---|---|
| Price | $20.89 | $18.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $23.14 | ★ $27.50 |
| AVG Volume (30 Days) | 933.7K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.48% | N/A |
| EPS Growth | ★ 538.46 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $0.85 | N/A |
| P/E Ratio | $6.22 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $15.75 | $5.95 |
| 52 Week High | $30.29 | $62.75 |
| Indicator | ENR | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 46.85 |
| Support Level | $19.49 | $18.46 |
| Resistance Level | $20.94 | $19.24 |
| Average True Range (ATR) | 0.75 | 1.06 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 53.06 | 14.01 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.